BioSpace News Archive

Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that Jeff Albers, Blueprint Medicines’ Chief Executive Officer, will participate virtually in a fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced further STRO-002 updated interim Phase 1 safety and preliminary efficacy data in ovarian cancer,

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the publication in Science Translational Medicine of the full results of the Phase 1/2a data for its lead product candidate, FB-401. FB-401, a live biotherapeutic consisting of specifically selected strains of commensal Roseomonas mucosa , was studied in an open-label Phase 1/2a trial in atopi

Acquisition Launches NovAccess Shift, Focusing on Diagnostics and Therapeutics in Cancer

An investigator-initiated study (IIS) supported by Octapharma USA has reported that intravenous immunoglobulin (IVIg) significantly improved hypoxia and reduced hospital length of stay and progression to mechanical ventilation in patients with COVID-19 pneumonia

Virtual two-day event to feature guest appearance by Dr. Anthony Fauci and sessions open to public for the first time ever.

Syapse Learning Health Network delivers real-world data insights to enable the AMITA Health Cancer Institute to provide high-quality patient-centered care

Allegheny Health Network (AHN) today announced the appointment of Margaret Larkins-Pettigrew, MD, MEd, MPPM, FACOG, as the health system’s first Chief Clinical Diversity & Inclusion Officer (CCDIO).

Leia Inc. and Infuse Medical have joined forces to revolutionize medical training and education with immersive 3D and 2D educational experiences.

Minnetronix Medical, the company known for 25 years of developing and manufacturing products for medical device companies throughout the world, today announced that it has received FDA clearance for its first platform product: the MindsEye™ Expandable Port for neurosurgical procedures.